Bacterial superinfection pneumonia in SARS-CoV-2 respiratory failure
Authors:
- Chiagozie O. PickensCPChiagozie O. Pickens
- Catherine A. GaoCGCatherine A. Gao
- Michael CutticaMCMichael Cuttica
- Sean B. SmithSSSean B. Smith
- Lorenzo PesceLPLorenzo Pesce
- Rogan GrantRGRogan Grant
- Mengjia KangMKMengjia Kang
- Luisa Morales-NebredaLMLuisa Morales-Nebreda
- Avni A. BavishiABAvni A. Bavishi
- Jason ArnoldJAJason Arnold
- Anna PawlowskiAPAnna Pawlowski
- Chao QiCQChao Qi
Preprint
Abstract
Background: Severe community-acquired pneumonia secondary to SARS-CoV-2 is a leading cause of death. Current guidelines recommend patients with SARS-CoV-2 pneumonia receive empirical antibiotic therapy for suspected bacterial superinfection, but little evidence supports these recommendations. Methods: We obtained bronchoscopic bronchoalveolar lavage (BAL) samples from patients with SARS-CoV-2 pneumonia requiring mechanical ventilation. We analyzed BAL samples with multiplex PCR and quantitative culture to determine the prevalence of superinfecting pathogens at the time of intubation and identify episodes of ventilator-associated pneumonia (VAP) over the course of mechanical ventilation. We compared antibiotic use with guideline-recommended care. Results: The 179 ventilated patients with severe SARS-CoV-2 pneumonia discharged from our hospital by June 30, 2020 were analyzed. 162 (90.5%) patients had at least one BAL procedure; 133 (74.3%) within 48 hours after intubation and 112 (62.6%) had at least one subsequent BAL during their hospitalization. A superinfecting pathogen was identified within 48 hours of intubation in 28/133 (21%) patients, most commonly methicillin-sensitive Staphylococcus aureus or Streptococcus species (21/28, 75%). BAL-based treatment reduced antibiotic use compared with guideline-recommended care. 72 patients (44.4%) developed at least one VAP episode. Only 15/72 (20.8%) of initial VAPs were attributable to multidrug-resistant pathogens. The incidence rate of VAP was 45.2/1000 ventilator days. Conclusions: With use of sensitive diagnostic tools, bacterial superinfection at the time of intubation is infrequent in patients with severe SARS-CoV-2 pneumonia. Treatment based on current guidelines would result in substantial antibiotic overuse. The incidence rate of VAP in ventilated patients with SARS-CoV-2 pneumonia are higher than historically reported.Keywords
This publication has 31 references indexed in Scilit:
- Co-infections in people with COVID-19: a systematic review and meta-analysisJournal of Infection, 2020
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BALChest, 2019
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumoniaEuropean Respiratory Journal, 2017
- Improved Detection of Respiratory Pathogens by Use of High-Quality Sputum with TaqMan Array Card TechnologyJournal of Clinical Microbiology, 2017
- Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired PneumoniaClinical Infectious Diseases, 2016
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. AdultsNew England Journal of Medicine, 2015
- Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections.Archives of Pathology & Laboratory Medicine, 2010
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated PneumoniaAnnals of Internal Medicine, 2000